NCT02082210View on ClinicalTrials.gov

A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 7, 2014

Primary Completion Date

December 5, 2017

Study Completion Date

January 24, 2018

Conditions

Advanced CancerGastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaHepatocellular CancerRenal Cell CarcinomaNon-Small Cell Lung Cancer

Interventions

DRUG

Emibetuzumab

Administered Intravenously (IV)

DRUG

Ramucirumab

Administered Intravenously (IV)

Trial Locations (4)

10065

Memorial Sloan Kettering Cancer Center, New York

37203

Tennessee Oncology PLLC, Nashville

02114-3117

Massachusetts General Hospital, Boston

02115

Dana Farber Cancer Institute, Boston

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT02082210 - A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer | Biotech Hunter | Biotech Hunter